Navigation Links
Tumor cell vaccination trial to promote anti-leukemia responses
Date:8/5/2013

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that most often affects older adults. CLL responds to bone marrow stem cell transplantation (allo-HSCT); however, the rate of relapse for CLL remains relatively high. A benefit of allo-HSCT is that treatment can result in the development of an anti-tumor response produced by the grafted cells and is associated with a low risk of cancer relapse.

In this issue of the Journal of Clinical Investigation, Catherine Wu and colleagues at the Dana Farber Cancer Institute in Boston report the results of a clinical trial that tested the effectiveness of vaccination with a CLL patient's own leukemia cells in the development of anti-tumor responses and relapse reduction. Patients with advanced CLL were vaccinated with their own irradiated tumor cells following allo-HSCT. Nearly 3 years after vaccination, 13 of the 18 vaccinated patients were in complete remission. The 6 patients that received the maximum vaccine dosage produced T cells that specifically reacted against tumors cells.

These results suggest that tumor cell vaccination has the potential to enhance anti-tumor responses following allo-HSCT.


'/>"/>

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Immune system molecule promotes tumor resistance to anti-angiogenic therapy
2. Suffocating tumors could lead to new cancer drugs
3. Digital PCR technology detects brain-tumor-associated mutation in cerebrospinal fluid
4. Protein complex linked to cancer growth may also help fight tumors, Moffitt researchers say
5. Voices Against Brain Cancer Comments on Discovery of Nano Drug That May Aid in Treatment of Brain Tumors
6. Compounds outsmart solid tumors malfunctioning machinery
7. Nano drug crosses blood-brain tumor barrier, targets brain-tumor cells and blood vessels
8. Self-perpetuating signals may drive tumor cells to spread
9. Suspicions confirmed: Brain tumors in children have a common cause
10. American Brain Tumor Association Conference to Help Patients/Caregivers Map Road to Wellness
11. Removal of tumor-associated immune cell protein decreases tumor progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... ... Hamlin Dental Group, multi-location dental office in North Hollywood , Van ... safe and effective options, and can be used alone or in conjunction with other ... care. , Dr. Hamid Reza of Hamlin Dental Group offers other treatments as well, ...
(Date:3/29/2017)... ... , ... VisualSP has helped over 1.5 million SharePoint users learn the content ... of its Help System for SharePoint was at the farm level. Enterprises using SharePoint ... , The company recently released a modified version of the Help System, VisualSP ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... team. Ruel Williamson brings his extensive knowledge of appraisals, property values, ad valorem ... the real estate valuation industry for more than 40 years. , “Ruel is ...
(Date:3/28/2017)... ... March 28, 2017 , ... City trips have soared 82% ... Trends Report). As travelers visit both urban destinations, they are faced with exploration ... exposure. In response, the outdoor industry has blurred the lines between fashion and ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® ... The program, developed in association with efforts by the American College of Surgeons, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Neurim Pharmaceuticals ("Neurim") and Exeltis announced today ... for Neurim,s new Rx PedPRM in Spain . ... Neurim,s paediatric prolonged-release ... children with Autism Spectrum Disorders (ASD) and neurogenetic diseases. It is ... The collaboration with Exeltis will help increase the accessibility of ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... Software Market Outlook: 2016-2022" report to their offering. ... The global patient safety ... of delivery, end-user, and geography. Patient safety has ... globe. The field has developed significantly in the last decade and ...
(Date:3/28/2017)... 2017 The U.S. Food and Drug ... adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is ... adequately by topical therapies, or those for whom ... used with or without topical corticosteroids. ... approving new and innovative therapies for patients with ...
Breaking Medicine Technology: